Furthermore, the phase III CheckMate 459 trial also demonstrated an improved OS for HCC patients with tumor cell PD-L1 > 1% (mOS 16.1 months vs. 8.6 months for sorafenib as first-line) (Sangro et al., 2020a). The gene discussed is CD274; the disease is neoplasm.